E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2009 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/18/09End of H1N1 'Second Wave' in Sight in the U.S., According to Quest Diagnostics
Quest Diagnostics Health Trends(TM) Report shows 75 percent decline in rates of 2009 H1N1 influenza virus testing, but H1N1 is still the predominant influenza strain infecting AmericansMADISON, N.J., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ag... 
Printer Friendly Version
12/09/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on January 22, 2010, to shareholders of record of Quest Diagnostics common stock on January 7, 2010. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, inform... 
Printer Friendly Version
12/03/09Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
Research to expand Leumeta(TM) line of blood plasma diagnostics; Scientists also describe technique for predicting response to Heparin surrogate MADISON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics (NYSE: DGX) will present duri... 
Printer Friendly Version
11/24/09Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference
MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 21st Annual Piper Jaffray Healthcare Conference in New York City. The presentation is scheduled for Wednesday, December 2, 2009 at 9:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operating inco... 
Printer Friendly Version
11/20/09Quest Diagnostics Announces Final Tender Offer Results
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 and any and all of its 7.50% Senior Notes due 2011 (collectively, the "Notes"). Additional terms and conditions of the Tender Offer are set forth in... 
Printer Friendly Version
11/20/09New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services, reveal that drug testing of hair specimens from employees and job applicants in the general U.S. workforce has tracked sharp downward trends in cocaine and methamphetamine use from 2005 to the first half of 2009 that mirror similar drops shown by urine testing. Data in the Quest Diagnostics D... 
Printer Friendly Version
11/20/09H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. In its most recent Quest Diagnostics Health Trends(TM) Report "Testing for H1N1 in America," ... 
Printer Friendly Version
11/18/092009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
Simplexa(TM) molecular RT-PCR test runs on the 3M Integrated Cycler; employs RT-PCR technologies comparable to 2009 H1N1 flu test used by World Health Organization MADISON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test k... 
Printer Friendly Version
11/17/09Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes
MADISON, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the determination of the pricing for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 (the "2010 Notes") and any and all of its 7.50% Senior Notes due 2011 (the "2011 Notes" and, together with the 2010 Notes, the "Note... 
Printer Friendly Version
11/13/09Quest Diagnostics to Speak at the Lazard Capital Markets 6th Annual Healthcare Conference
MADISON, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 17, 2009 at 10:55 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operatin... 
Printer Friendly Version
11/12/09Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
MADISON, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has commenced a cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 (the "2010 Notes") and any and all of its 7.50% Senior Notes due 2011 (the "2011 Notes" and, together with the 2010 Notes, the "Notes"). Additional terms and conditions of ... 
Printer Friendly Version
11/12/09Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $750,000,000 in aggregate principal amount in two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionall... 
Printer Friendly Version
11/02/09Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference
MADISON, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Oppenheimer 20th Annual Healthcare Conference in New York City. The presentation is scheduled for Wednesday, November 4, 2009 at 11:25 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operatin... 
Printer Friendly Version
11/02/09New ChartMaxx(R) V5.5 with Recovery Audit Contractor (RAC) Manager Helps Hospitals Handle RAC Audit Requests
CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- MedPlus®, the healthcare information technology subsidiary of Quest Diagnostics® Incorporated (NYSE: DGX), today announced the release of ChartMaxx® V5.5, an upgrade to its industry-leading ChartMaxx document management and imaging solution. With the new optional RAC Manager, ChartMaxx V5.5 helps health care providers tie together electronic forms, discrete data, color coded timers and e-mail alerts, dashboard reports, and release of infor... 
Printer Friendly Version
10/27/09New Mexico Health Information Collaborative (NMHIC) Appointed as State's Official Health Information Exchange (HIE)
ALBUQUERQUE, N.M., Oct. 27 /PRNewswire-FirstCall/ -- Maggie Gunter, PhD, president of the New Mexico Health Information Collaborative (NMHIC), announced today that the organization has been appointed as the state's official health information exchange (HIE) by New Mexico Governor Bill Richardson. NMHIC will create the health information exchange infrastructure to connect New Mexico's health care providers through a contract with its technology partner, MedPlus, the healthcare info... 
Printer Friendly Version
10/26/09MedPlus Maintains Top Ranking in KLAS Industry Report
MADISON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), announced today that it has been recognized as the health care industry's number one Document Management & Imaging (DMI) vendor for its ChartMaxx® enterprise-wide electronic patient record system in the KLAS (1) Enterprise DMI: Finding the Right Stepping-Stone to Full EMR report issued on October 2, 2009 (www.KLASresearch.com). Char... 
Printer Friendly Version
10/22/09Quest Diagnostics Health Trends (TM) Report on 2009 H1N1 Influenza
Click here for the full report, including charts and tables - In 2009, the H1N1 influenza A virus emerged as the first influenza pandemic in forty years. As the leading diagnostic testing company in the U.S. - and the only provider of two commercial tests authorized by the FDA for emergency use* - Quest Diagnostics is uniquely positioned to provide insights into the behavior of this new pandemic virus and its impact on Americans. In our latest Quest Diagnostics Health TrendsTM Report, we ... 
Printer Friendly Version
10/20/09Quest Diagnostics Reports Strong Performance in Third Quarter 2009
- Total revenues of $1.9 billion, up 3.9% - Diluted earnings of $1.02 per share, up 26% - Cash flow from operations of $374 million, up 14% - 2009 EPS outlook increased to a range of $3.80 to $3.85 MADISON, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2009, income from continuing operations rose to $192 million, or $... 
Printer Friendly Version
10/16/09FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics' Focus Diagnostics
MADISON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today issued a second emergency use authorization (EUA) to Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated (NYSE: DGX), for its 2009 H1N1 influenza virus test. With the EUA, Focus Diagnostics is the only company in the U.S. to offer test kits for detecting the pandemic 2009 H1N1 virus that the FDA has authorized for emergency use by CLIA h... 
Printer Friendly Version
10/07/09Quest Diagnostics Brings Genetic Testing for Plavix(R) Response to Coronary Stent Patients at Scripps Health
First saliva-based cardiovascular disease test from Quest Diagnostics identifies gene variants implicated in potentially lethal reaction to popular anti-clotting drug MADISON, N.J., Oct. 7 /PRNewswire/ -- DNA testing for gene variants that can increase the risk of major coronary events in certain patients taking the anti-clotting drug Plavix® (clopidogrel bisulfate) is now being performed by Quest Diagnostics (NYSE: DGX) for Scripps Health patients electing to undergo coronary stent pro... 
Printer Friendly Version
10/06/09Quest Diagnostics to Release Third Quarter Financial Results on October 20, 2009
MADISON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its third quarter results will be made public on Tuesday, October 20, before the market opens. The company will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio w... 
Printer Friendly Version
10/05/09Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs
MedPlus Centergy(R) Clinical Portal and ChartMaxx(R) Enable Streamlined Chart Completion Online MADISON, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), pro... 
Printer Friendly Version
09/23/09Quest Diagnostics Empowers the Nation's Physicians to Immediately Embrace ePrescribing
Company to Enable All Care360(TM) Labs & Meds Users to Use ePrescribing Feature; Invites All U.S. Physicians to Use Care360 ePrescribing Risk Free for Six Months MADISON, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX) today announced plans to make it easy for every physician in the United States to quickly embrace digital healthcare technology with a six-month, risk-free trial of its Care360(TM) ePrescribing service. For physicians currently using its Care360 Labs & ... 
Printer Friendly Version
09/11/09U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass
MADISON, N.J. and FREMONT, Calif., Sept. 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malig... 
Printer Friendly Version
09/11/09Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
MADISON, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Merrill Lynch Global Healthcare Conference in London, United Kingdom. The presentation is scheduled for Tuesday, September 15, 2009 at 9:50 a.m. Greenwich Mean Time, 5:50 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance fo... 
Printer Friendly Version
09/04/09Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
MADISON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America). The company is in its sixth year on the World Index (since 2004) and in its fifth on the North American Index (since 2005). According to Sustainabl... 
Printer Friendly Version
08/20/09Focus Diagnostics Launches 2009 H1N1 Flu Test Kit to Commercial Laboratories in the U.S.
First test for detecting the new virus to be authorized by FDA for use by CLIA high-complexity labs during pandemic emergency CYPRESS, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated (NYSE: DGX), today announced that its Influenza A H1N1 (2009) Real Time RT-PCR test is now available as a test kit for use by "high complexity" clinical laboratories in the U.S. The test quali... 
Printer Friendly Version
08/12/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 19, 2009, to shareholders of record on October 2, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, info... 
Printer Friendly Version
07/24/09FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business
MADISON, N.J., July 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to the company's Focus Diagnostics business for its test for detecting the 2009 H1N1 influenza virus (the "pandemic flu virus"), a strain of influenza A virus initially referred to as the swine flu virus. T... 
Printer Friendly Version
07/21/09Quest Diagnostics Reports Strong Performance in Second Quarter 2009
Total revenues of $1.9 billion, up 3.5%; Diluted earnings of $1.00 per share, up 20%; 2009 EPS outlook increased to between $3.70 and $3.80 MADISON, N.J., July 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2009, income from continuing operations rose to $188 million, or $1.00 pe... 
Printer Friendly Version
07/20/09Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care
Patient-Based Record Improves Quality, Safety and Efficiency MADISON, N.J., July 20 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that NYCLIX is now sharing key patient data electronically among ten unaffiliated healthcare organizations across New York City using the company's Centergy(TM) suite of integrated health information exchange (HIE) solutions. NYCLIX partner hospital... 
Printer Friendly Version
07/09/09Quest Diagnostics To Release Second Quarter Financial Results
MADISON, N.J., July 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its second quarter results will be made public on Tuesday, July 21, before the market opens. The company will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio... 
Printer Friendly Version
06/24/09Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles'
National Business Group on Health Recognizes HealthyQuest Program for Fifth Consecutive Year MADISON, N.J., June 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health (NBGH) has awarded its 2009 Best Employers for Healthy Lifestyles Platinum Award to the company for its HealthyQuest employee wellness program. The Platinum Award... 
Printer Friendly Version
06/22/09Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
Agreement with Medical Automation Systems, Inc. Will Add RALS(R)-Plus Module to Company's Hemoglobin and Glucose Handheld Devices MADISON, N.J., June 22 /PRNewswire-FirstCall/ -- HemoCue Inc., the U.S. point-of-care testing distribution subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with Medical Automation Systems, Inc. (MAS) for the development of a RALS(R)-Plus module for the HemoCue 201 DM analyzer whole blood systems fo... 
Printer Friendly Version
06/17/09Quest Diagnostics Announces Final Tender Offer Results
MADISON, N.J., June 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer to purchase up to $200 million total aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are describe... 
Printer Friendly Version
06/15/09Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
MADISON, N.J., June 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies 3rd Annual Healthcare Conference in New York City on Thursday, June 18, 2009. The Quest Diagnostics presentation is scheduled to begin at 11:45 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registere... 
Printer Friendly Version
06/12/09New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory developed test designed to help physicians determine whether a patient with a history of HIV drug resistance will respond to th... 
Printer Friendly Version
06/12/09Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the determination of the pricing for its previously announced cash tender offer to purchase up to $200 million total aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender off... 
Printer Friendly Version
06/08/09Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
MADISON, N.J., June 8, 2009 /PRNewswire-FirstCall via COMTEX/ -- A study in the June issue of Clinical Gastroenterology and Hepatology, published by Elsevier, demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel may help physicians more accurately diagnose and stage liver fibrosis in patients with chronic hepatitis C (HCV), potentially alleviating the need for liver biopsy, the standard of care for staging fibrosis, in a particular subset of patients. The Hepascore test pane... 
Printer Friendly Version
06/08/09Quest Diagnostics to Speak at the William Blair & Company 29th Annual Growth Stock Conference
MADISON, N.J., June 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the William Blair & Company 29th Annual Growth Stock Conference in Chicago on Tuesday, June 9, 2009. The Quest Diagnostics presentation is scheduled to begin at 8:10 a.m. Central Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth ... 
Printer Friendly Version
06/04/09Health Care Finance to Implement District's First Medicaid 'Patient Data Hub' Using MedPlus Technology
Health Information Exchange for Medicaid Beneficiaries, Powered by MedPlus Centergy(TM) Solutions, will Connect Physicians, Hospitals and Clinics to Accelerate Access to Patient Information and Better Health Outcomes WASHINGTON, and MADISON, N.J., June 4 /PRNewswire-FirstCall/ -- The Department of Health Care Finance, DHCF, the District's Medicaid agency, announced the selection of MedPlus, the health information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), ... 
Printer Friendly Version
06/03/09Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that, as of 5:00 p.m., New York City time, on June 2, 2009 (the "Early Tender Date"), the following principal amounts of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes") have been validly tendered and not validly withdrawn in connection with its previously ann... 
Printer Friendly Version
06/03/09Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program
Quest4Health.com Lauded in Healthcare Category for 'Visionary Application of Information Technology to Promote Positive Social and Economic Progress' MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its subsidiary Quest Diagnostics India Pvt. Ltd. has been recognized as a Laureate by the International Data Group's (IDG) Computerworld Honors Program. The a... 
Printer Friendly Version
06/02/09Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite
Agreement to Distribute MEC HbA1c Test To Provide Physicians in U.S. and Europe With Fast, Accurate Near-Patient Test for Diabetes Monitoring MADISON, N.J., June 2 /PRNewswire-FirstCall/ -- HemoCue AB, an international company in the field of point-of-care testing and a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with MEC Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) A1c point-of-care test in the Uni... 
Printer Friendly Version
06/01/09Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
EGFR Pathway Test analyzes in sequential reflex fashion more mutations potentially inhibiting anti-EGFR therapy response in metastatic colorectal cancer patients MADISON, N.J., June 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today launched the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identify... 
Printer Friendly Version
05/28/09Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL. Quest Diagnostics Incorporated (NYSE: DGX) is the world's leading provider of diagnostic testing, informatio... 
Printer Friendly Version
05/19/09Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., May 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has commenced a cash tender offer to purchase up to $200 million aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are described in the Offer to Purchase date... 
Printer Friendly Version
05/15/09Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online
MADISON, N.J., May 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX) announced today that it will enable patients and their physicians to share diagnostic laboratory test results, using Microsoft HealthVault(TM). The connection will enable physicians who use Quest Diagnostics' Care360(TM) patient-centric physician portal to securely transfer, at a patient's request, diagnostic laboratory test results in a HIPAA-compliant format into the patient's protected account... 
Printer Friendly Version
05/15/09Quest Diagnostics to Speak at the Deutsche Bank 34th Annual Healthcare Conference
MADISON, N.J., May 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Deutsche Bank 34th Annual Healthcare Conference in Boston on Tuesday, May 19, 2009. The Quest Diagnostics presentation is scheduled to begin at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth of approxima... 
Printer Friendly Version
05/14/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 20, 2009, to shareholders of record on July 6, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information ... 
Printer Friendly Version
05/11/09Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
Real-time PCR test validated using clinical specimens confirmed positive for Influenza A H1N1 Swine-origin flu virus MADISON, N.J., May 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction (PCR) test to aid in identifying Influe... 
Printer Friendly Version
05/08/09Quest Diagnostics Announces Annual Shareholders Meeting Webcast
MADISON, N.J., May 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will conduct its annual meeting of shareholders on Thursday, May 14th at 10:30 am ET. An audio webcast will be accessible through the Investor Relations section of the company Web site at www.QuestDiagnostics.com/investor. For those unable to listen to the live broadcast, a replay will be available on the Web site... 
Printer Friendly Version
05/07/09Quest Diagnostics to Speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference
MADISON, N.J., May 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference in New York City on Tuesday, May 12, 2009. The Quest Diagnostics presentation is scheduled to begin at 1:20 p.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue... 
Printer Friendly Version
05/06/09Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
Methamphetamine Use Drops While Amphetamine Use Continues to Rise Random Drug Testing Programs May Deter Use, Data Show MADISON, N.J., May 6 /PRNewswire/ -- Cocaine use among U.S. employees and job applicants in the general U.S. workforce declined sharply in 2008, according to the annual Quest Diagnostics Drug Testing Index(TM) (DTI), based on 5.7 million urine drug tests performed last year by Quest Diagnostics (NYSE: DGX), the nation's leading provider of drug testing se... 
Printer Friendly Version
04/27/09Quest Diagnostics Discovers New Genetic Mutations Affecting Cystic Fibrosis Screening
Company's Scientists also Enhance Industry Standards for Quality Screening in Three Articles Published in The Journal of Molecular Diagnostics MADISON, N.J., April 27 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists provide new insights into genetic factors affecting the accuracy and quality of Cystic Fibrosis (CF) carrier and newborn screening in three separate articles published in the May 2009 issue of The Journal of Molecular Diagnostics. Quest Diagnostics Incorporated (N... 
Printer Friendly Version
04/21/09Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
Diluted earnings per share of $0.89, up 24% Total revenues of $1.8 billion, up 1.3% Cash flow from operations of $273 million, up 73% 2009 EPS outlook increased to between $3.65 and $3.75 MADISON, N.J., April 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2009, income from continuing operations was $169 mi... 
Printer Friendly Version
04/15/09Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
MADISON, N.J., April 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced it finalized resolution of the previously disclosed federal government investigation related to certain test kits manufactured by NID, a test kit manufacturing subsidiary closed voluntarily in 2006. Quest Diagnostics cooperated with the government since its investigation began in 2004. Quest Diagnostics will pay $262 million to settle the civil investigation. While... 
Printer Friendly Version
04/13/09Quest Diagnostics to Release First Quarter Financial Results
MADISON, N.J., April 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its first-quarter results will be made public on Tuesday, April 21, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcas... 
Printer Friendly Version
04/03/09MedPlus Centergy(TM) Suite for Hospitals and HIEs Paves a New, Faster Path to Healthcare Information Technology Benefits
The Choice of Leading Nationwide Health Information Network Contractors and Health Information Exchanges Connects Physicians to the Nation's Largest Provider Network Visit MedPlus at HIMSS Booth 2362 in Chicago, April 5-9 CINCINNATI, April 3 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today introduced a suite of clinical portal and data exchange services for hospitals and health information ... 
Printer Friendly Version
03/31/09Quest Diagnostics to Support Walgreens and Take Care Health Systems' Offer of Free Health Services by Providing Certain Free Laboratory Testing
MADISON, N.J., March 31 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will provide strep and urine cultures and other select laboratory testing services for free to qualified patients served through the Take Care Recovery Plan, which is an offer, announced by Walgreens (NYSE, Nasdaq: WAG) and Take Care Health Systems, to provide free health care services at Take Care Clinics. The offer... 
Printer Friendly Version
03/17/09Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
Test aiding diagnosis of mental retardation, birth defects, and autism spectrum and developmental disorders now approved for use on patients in New York MADISON, N.J., March 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its ClariSure(TM) microarray-based comparative genomic hybridization (aCGH) postnatal test is now available for testing on patients in th... 
Printer Friendly Version
03/12/09Jon R. Cohen, M.D., Named Senior Vice President and Chief Medical Officer at Quest Diagnostics
Former Chief Policy Advisor to New York Governor David A. Paterson is distinguished vascular surgeon and healthcare policy expert MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that Jon R. Cohen, M.D., Senior Advisor to New York Governor David A. Paterson, will join the company as Senior Vice President and Chief Medical Officer on March 30, 20... 
Printer Friendly Version
03/09/09Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference
MADISON, N.J., March 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital Healthcare Conference in Miami on Tuesday, March 10, 2009. The Quest Diagnostics presentation is scheduled to begin at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth of approximately 3%, ... 
Printer Friendly Version
03/03/09Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List
Ranks second overall and first for long-term investment and social responsibility in industry category MADISON, N.J., March 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to FORTUNE magazine's list of the World's Most Admired Companies. Quest Diagnostics ranked second in the "Health Care" category of "Pharmacy and Other Services." The 2009 ranking is the seco... 
Printer Friendly Version
02/20/09Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
Study published in New England Journal of Medicine employs Quest Diagnostics' blood-based leukemia testing MADISON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine. The finding may lead to a better understanding of cellular changes that characterize the ... 
Printer Friendly Version
02/11/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb 11, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share payable on April 20, 2009, to shareholders of record on April 6, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, informati... 
Printer Friendly Version
01/26/09Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
MADISON, N.J., Jan 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- - Diluted earnings per share of $0.87, up 10% - Total revenues of $1.8 billion, up 1.7% - Cash flow from operations improved to $363 million - 2009 EPS expected to be between $3.50 to $3.70 per diluted share Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2008, income from continu... 
Printer Friendly Version
01/26/09Quest Diagnostics' Board Authorizes $500 Million in Share Repurchases
MADISON, N.J., Jan. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors has authorized $500 million in share repurchases. The company had approximately 190 million common shares outstanding as of December 31, 2008. "This repurchase program demonstrates confidence in our performance and commitment to increasing shareholder value," said Surya N. M... 
Printer Friendly Version
01/12/09Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
MADISON, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth-quarter and full year 2008 results and provide financial guidance for 2009 on Monday, January 26, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the co... 
Printer Friendly Version